ROIV Earnings Prediction
The chart below shows how ROIV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ROIV sees a -1.41% change in stock price 10 days leading up to the earnings, and a +1.04% change 10 days following the report. On the earnings day itself, the stock moves by +1.87%. This data can give you a slight idea of what to expect for the next quarter's release.
ROIV Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
37.14M
117.80%
0.11%
Gross Margin
90.12%
14.12%
-1.18%
Operating Margin
-774.17%
-65.08%
3.90%
Net Margin
13658.23%
705.10%
-1630.37%
EPS
6.03
1330.61%
-1607.50%
No Data Available
ROIV Earnings Analysis
Roivant Sciences Ltd Corporation (ROIV.O) Earnings Conference Call
Positive
Earnings Surprise Report: Roivant Sciences Ltd. reported an EPS of $0.23, significantly beating expectations of $-0.24.
Strong Cash Position: The company has a robust cash position of $5.2 billion as of December 31, 2024, which supports ongoing and future projects.
IND Clearances and Trials: Roivant has successfully cleared six INDs at Abutavant, with trials either initiated or set to begin by March 2026.
Debt Elimination Through Sale: The sale of dermaVant to Organon generated approximately $259 million, contributing to the company's strong financial position and eliminating all debt.
Share Buyback Authorization: Roivant has authorized an additional $500 million for share buybacks, having already repurchased about $1 billion in shares as of the end of 2024.
Negative
R&D Expense Increase: Reported R&D expenses of $142 million, which is a significant increase compared to the previous quarter, indicating rising costs without corresponding revenue growth.
G&A Expense Impact: General and Administrative (G&A) expenses also reached $142 million, reflecting a substantial financial burden on the company amidst ongoing operational challenges.
Revenue Generation Concerns: Despite a cash balance of $5.2 billion, the company has not generated significant revenue from its product pipeline, raising concerns about long-term sustainability.
Clinical Trial Delays Impact: The company has faced delays in clinical trials, which could impact the timeline for potential product launches and revenue generation, particularly in the dermatomyositis indication.
Litigation Impact on Profitability: Ongoing litigation with Moderna and Pfizer BioNTech could result in substantial legal costs and distract from core business operations, potentially affecting future profitability.
ROIV FAQs
How does ROIV typically perform around its earnings report dates?
Is Roivant Sciences Ltd (ROIV) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ROIV Earning Call Sentiment
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call Transcript
ROIV.O
-2.78%Positive
The earnings call revealed strong financial performance, with a positive EPS surprise and a robust cash position. The company's shareholder return plan, including significant share buybacks, is a positive indicator. Despite regulatory and competitive risks, optimistic guidance on clinical trials and potential blockbuster revenues provide a positive outlook. The Q&A section didn't reveal major concerns that would significantly alter the sentiment. Overall, the combination of financial strength, strategic initiatives, and optimistic guidance outweighs the risks, suggesting a positive stock price movement.
